EUVIMEDEUVIMED entdecken
Open Access

Allogeneic Stem Cell Transplantation—A Salvage Option for High‐Risk Chronic Lymphocytic Leukemia Patients: A 15‐Year Single‐Center Experience

Natalia B Mikhailova, Maria I Kislova iD, Maria O Ivanova, Julia A Zhuravleva, Elena A Dmitrieva iD, Elena V Kondakova, Anna G Smirnova, Yana V Krylova, Olga V Kudyasheva, Yulia Y Vlasova, Anastasya V Beynarovich iD, Nikita P Volkov und 3 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Natalia B Mikhailova und 14 weiteren Autor:innen. Beteiligte Einrichtung: R.M.Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Salvage Therapy, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of allogeneic hematopoietic cell transplantation (alloSCT) in chronic lymphocytic leukemia (CLL) has decreased in recent years due to the emergence of new effective targeted agents for the treatment of this disease. However, for a certain group of heavily pretreated or high‐risk CLL patients with no other therapeutic options, allo‐SCT remains important. Due to the fact that in most high‐risk CLL patients it is possible to achieve durable response as a result of Bruton's tyrosine kinase inhibitors (ВТК), BCL‐2 inhibitor and especially in their combined application, including in the first line of therapy, the choice of time point for alloSCT becomes relevant. In this retrospective study allo‐SCT was performed in 44 patients with the period from 2006 to 2023. Progression‐free survival was 79.2% at 12 months and 69.3% at 24 months. Similarly, overall survival was 81.4% at 12 months and 74% at 24 months. Graft—versus‐host disease relapse‐free survival was 57%. Despite small sample size, our study demonstrates that alloSCT has become a significantly safer procedure in patients with CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellSalvage TherapyHematopoietic Stem Cell TransplantationHumansFemaleTransplantation, HomologousMaleRetrospective StudiesMiddle AgedAgedAdult

Autor:innen und Institutionen

  • R.M.Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia.
  • Botkin Hospital, Moscow, Russia.

ORCID-Profile: Maria I Kislova, Elena A Dmitrieva, Anastasya V Beynarovich, Ivan S Moiseev

Zitieren

APA

Mikhailova, N. B., Kislova, M. I., Ivanova, M. O., Zhuravleva, J. A., Dmitrieva, E. A., Kondakova, E. V., Smirnova, A. G., Krylova, Y. V., Kudyasheva, O. V., Vlasova, Y. Y., Beynarovich, A. V., Volkov, N. P., Moiseev, I. S., Nikitin, E. A., & Kulagin, A. D. (2026). Allogeneic Stem Cell Transplantation—A Salvage Option for High‐Risk Chronic Lymphocytic Leukemia Patients: A 15‐Year Single‐Center Experience. Hematological Oncology. https://doi.org/10.1002/hon.70229

Vancouver

Mikhailova NB, Kislova MI, Ivanova MO, Zhuravleva JA, Dmitrieva EA, Kondakova EV, et al. Allogeneic Stem Cell Transplantation—A Salvage Option for High‐Risk Chronic Lymphocytic Leukemia Patients: A 15‐Year Single‐Center Experience. Hematological Oncology. 2026. doi:10.1002/hon.70229

BibTeX
@article{Mikhailova2026,
  author = {Mikhailova, Natalia B and Kislova, Maria I and Ivanova, Maria O and Zhuravleva, Julia A and Dmitrieva, Elena A and Kondakova, Elena V and Smirnova, Anna G and Krylova, Yana V and Kudyasheva, Olga V and Vlasova, Yulia Y and Beynarovich, Anastasya V and Volkov, Nikita P and Moiseev, Ivan S and Nikitin, Eugene A and Kulagin, Alexander D},
  title = {Allogeneic Stem Cell Transplantation—A Salvage Option for High‐Risk Chronic Lymphocytic Leukemia Patients: A 15‐Year Single‐Center Experience},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70229}
}
Kostenlos starten →